IBD Management in Women of Childbearing Age: A Holistic Approach to Family Planning
  • CME

In this interactive video, gain expert insights on helping women manage their IBD during their childbearing years, including addressing concerns about fertility, drug safety, and managing flares.
Marla Dubinsky, MD
Uma Mahadevan, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: March 25, 2020 Expiration: March 24, 2021
Multimedia IBD Management in Women of Childbearing Age: A Holistic Approach to Family Planning
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME/CE posttest and evaluation.
Overview (4 minutes)
Clinical overview of IBD in women of childbearing age, including common misperceptions.
Launch Overview (4 minutes)
IBD, Fertility, Genetics (10 minutes)
Evidence-based discussion of fertility rates in women with IBD.
Launch IBD, Fertility, Genetics (10 minutes)
IBD Treatments in Conception, Pregnancy, Breastfeeding (21 minutes)
Expert discussion of managing therapeutic decisions for IBD during pregnancy.
Launch IBD Treatments in Conception, Pregnancy, Breastfeeding (21 minutes)
IBD and Delivery (8 minutes)
Experts address misperceptions about delivery options for pregnant women with IBD.
Launch IBD and Delivery (8 minutes)
Postdelivery Care (10 minutes)
Preventing and managing postpartum flares in women with IBD.
Launch Postdelivery Care (10 minutes)
Summary (4 minutes)
Experts summarize the key take-home messages regarding managing IBD in women of childbearing age.
Launch Summary (4 minutes)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize the evidence for successful pregnancy in women with IBD that can be conveyed to patients who desire to become pregnant
  • Outline the key tenets of caring for women with IBD who wish to become pregnant, including preconception counseling and the importance of a multidisciplinary team
  • Detail preconception IBD medical management recommended by the AGA regarding conventional and biologic therapies

Acknowledgements

Provided by the American Gastroenterological Association

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Supported by an educational grant from
Pfizer Inc.

Information on this Educational Activity

Disclosure of Conflicts of Interest

The American Gastroenterological Association requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the AGA policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Faculty

Uma Mahadevan, MD

Professor of Medicine
Division of Gastroenterology
Department of Medicine
University of California, San Francisco
Co-Director
UCSF Center for Colitis and Crohn's Disease
San Francisco, California

Uma Mahadevan, MD, had disclosed that she has received consulting fees from AbbVie, Allergan, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Takeda and funds for research support from Celgene and Pfizer.
Marla Dubinsky, MD

Chief of Pediatric Gastroenterology and Nutrition
Co-Director, 
Susan and Leonard Feinstein IBD Clinical Center
Icahn School of Medicine
Mount Sinai, New York

Marla Dubinsky, MD, has disclosed that she has received consulting fees from AbbVie, Arena, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Pfizer, Prometheus, and Takeda; has received funds for research support from AbbVie, Janssen, Pfizer, and Prometheus; has received royalties from Mi Test Health; and has ownership interest in Trellus Health.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Lillian McVey

Editorial Contributor

Lillian McVey has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The American Gastroenterological Association, Clinical Care Options, and the activity supporter do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the American Gastroenterological Association, Clinical Care Options, and the activity supporter. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for gastroenterologists, primary care clinicians, OB/GYN healthcare providers, and other clinicians who care for women of childbearing age with IBD who hope to become pregnant and/or are considering planning a family.

Goal

The goal of this activity is to improve the competence of learners to apply evidence-based medicine and expert commentary to develop preconception strategies that can help to ensure safe and effective IBD control before and during pregnancy.

Accreditation Statement

American Gastroenterological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

American Gastroenterological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 25, 2020, through March 24, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Uma Mahadeven, MD, and Marla Dubinsky, MD: expert commentary on preconception strategies to ensure safe, effective IBD control before and during pregnancy

Marla Dubinsky, MD Uma Mahadevan, MD Released: March 25, 2020

Gary R. Lichtenstein, MD, and Uma Mahadevan, MD: comparable efficacy, risks, and real-world data on biologic and small molecules therapies for moderate to severe UC

Gary Lichtenstein Headshot Gary R. Lichtenstein, MD Uma Mahadevan, MD Released: January 24, 2020

David Schwartz, MD, and Baldeep Pabla, MD: expert viewpoint on data from 2019 Crohn’s & Colitis Congress for mirikizumab, SHP647, ustekinumab in IBD

Baldeep S. Pabla, MD, MSCI David A. Schwartz, MD, FACG, AGAF Released: June 26, 2019

D. Brent Polk, MD, expert viewpoint on data from Crohn’s & Colitis Congress 2019 on proactive vs reactive drug monitoring approaches in IBD

D. Brent Polk, MD, AGAF Released: June 7, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?